Drug intelligence / Profile preview

6-hydroxybenziodarone

Development stage: Unknown
Lead developer: University of Toyama

Overview

6-hydroxybenziodarone: sourced facts only. name: "An ex vivo competitive binding assay using a fluorogenic probe showed that benziodarone and 6-hydroxybenziodarone were highly potent for selective binding to transthyretin in human plasma." [PMID:37311373]; target: "An ex vivo competitive binding assay using a fluorogenic probe showed that benziodarone and 6-hydroxybenziodarone were highly potent for selective binding to transthyretin in human plasma." [PMID:37311373]; developer: "Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan. Electronic address: [email protected]." [PMID:37311373]

Targets

TTR (Transthyretin)

Beyond the preview

Go deeper on 6-hydroxybenziodarone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-hydroxybenziodarone.